Skip to main content

Closed

EXEL: Exelixis, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+18.5% / yr

Operating margin39.4%

ROIC35.0%

Financially safe

Stretched

Debt / equity0.09×

Interest coverage0.0×

Current ratio3.26×

Valuation

Unrated

P/E ratio17.0×

Exelixis, Inc.

EXELNASDAQ Global Select·USD·Closed

Exelixis, Inc.

EXELNASDAQ·USD·Closed

$53.03

−5.25%

$53.03

−$2.94 (5.25%)

52W Range

81thpctl

Volume

1.10×avg

Mkt Cap

13.33BUSD

P/E

17.0TTM

Div Yield

–ann

52W Range

81thpctl

Volume

1.10×avg

Market Cap

13.33BUSD

P/E Ratio

17.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings